Clinical Trial Update: Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) [Phase 2]

View source ↗

Summary

Phase 2 trial ZENOBIA evaluating Zanzalintinib in combination with Durvalumab and Tremelimumab for unresectable hepatocellular carcinoma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Anwaar Saeed | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING